enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

Tue, 12 May 2026 09:02:00 EST

First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve

IDE approval positions enVVeno to advance what could become the first effective treatment option for the approximately 3 million U.S. patients suffering from DVI

Watch the "What This Means" video

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

Thu, 07 May 2026 08:05:00 EST

Company ended the first quarter with approximately $25 million in cash and investments

Capital on hand should fund operations through multiple key milestones into Q3 2027

Company recently received FDA IDE approval to commence TAVVE U.S. Pivotal Study for non-surgical replacement venous valve, enVVe System

TAVVE site selection is underway with patient enrollment...

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

Wed, 29 Apr 2026 08:05:00 EST

First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial
Clinical site activation and patient enrollment expected to commence later this year
Large unmet clinical need for approximately 3 million U.S. patients with severe deep Chronic Venous Insufficiency
Potential multi-billion-dollar untapped U.S. market
Company...

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe® System

Fri, 27 Mar 2026 08:30:00 EST

Company accelerated development of the enVVe^® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiation
Strong financial position expected to provide an operating runway into mid-2027 through the achievement of key clinical milestones

IRVINE, CA / ACCESS Newswire / March 27, 2026 /...

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

Wed, 04 Feb 2026 08:30:00 EST

Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed
Reports Cash and Investments of approximately $28 million as of the Year Ended December 31, 2025

IRVINE, CA / ACCESS Newswire / February 4, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the...

enVVeno Medical Announces Reverse Stock Split

Thu, 15 Jan 2026 08:00:00 EST

IRVINE, CA / ACCESS Newswire / January 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 35 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on January...

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

Wed, 26 Nov 2025 08:48:00 EST

Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, December 3^rd at 4:00 PM ET

IRVINE, CA / ACCESS Newswire / November 26, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief...

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

Thu, 13 Nov 2025 17:00:00 EST

IRVINE, CA / ACCESS Newswire / November 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received an unfavorable decision from the U.S. Food & Drug Administration ("FDA") in response to its supervisory appeal of the not-approvable letter...

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Fri, 31 Oct 2025 08:05:00 EST

- Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study
- Cash burn of $4.2 million in Q3 remains in line with projected quarterly range
- Ongoing engagement with FDA for supervisory appeal of the VenoValve PMA decision with feedback expected by the end of 2025

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

Fri, 26 Sep 2025 08:45:00 EST

Watch the "What This Means" video here

IRVINE, CA / ACCESS Newswire / September 26, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that

enVVeno Medical Updates Regulatory Status of VenoValve®

Mon, 15 Sep 2025 08:45:00 EST

IRVINE, CA / ACCESS Newswire / September 15, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it will file a request for supervisory appeal of the not-approvable letter from the Center for Devices and Radiological Health (CDRH) of the U.S. Food &...

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve®

Wed, 20 Aug 2025 07:00:00 EST

IRVINE, CA / ACCESS Newswire / August 20, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received a not-approvable letter from the U.S. Food & Drug Administration (FDA) in response to its Premarket Approval (PMA) application for...

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Fri, 15 Aug 2025 09:21:00 EST

- Live webcast on Thursday, August 21^stat 2:00 PM ET

IRVINE, CA / ACCESS Newswire / August 15, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it will present at the

Health Economic Study Shows That enVVeno Medical's VenoValve® Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

Wed, 06 Aug 2025 08:30:00 EST

Clinical data and cost-effectiveness analysis demonstrates the VenoValve would provide both better health outcomes and lower costs compared to current standard of care treatments
The VenoValve could potentially save $5.9 billion annually in healthcare costs for the approximately 2.5 million U.S. patients with severe CVI
Company to host live webcast with lead author of the cost-analysis...

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

Mon, 04 Aug 2025 09:05:00 EST

- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency
- FDA decision expected in 2H'2025
- Access the "What This Means" segment here

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Fri, 01 Aug 2025 08:00:00 EST

- Cash burn of $3.8 million in Q2 remains in line with projected quarterly range
- Cash and investments are sufficient to fund operations through Q3'2026 at current cash burn rate
- Commercial readiness activities underway for a phased launch of VenoValve® subject to FDA decision expected in 2H'2025
- IDE submission for enVVe® on track for...

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Tue, 22 Jul 2025 08:45:00 EST

- Video webcast now available on-demand

IRVINE, CA / ACCESS Newswire / July 22, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Rob Berman, CEO of enVVeno, participated...

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Fri, 06 Jun 2025 08:05:00 EST

Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline
83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS)
9.1 point average rVCSS improvement among the clinically meaningful...

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

Mon, 19 May 2025 08:05:00 EST

IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, announced the appointment of Jennifer Bright as Chief Financial Officer, effective today, May 19, 2025. Ms. Bright brings more than 25 years of financial and strategic leadership...

Three-Year VenoValve® First-in-Human Trial Data Published in the Annals of Vascular Surgery

Tue, 13 May 2025 08:45:00 EST

Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous competence and maintaining clinical benefits
Company has submitted PMA application for the VenoValve to the U.S. Food and Drug Administration (FDA) with a decision anticipated in the second half of...

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H25

Thu, 01 May 2025 08:05:00 EST

Cash Burn of $4.0 million in Q1 remains in line with projected quarterly range
Cash and investments on hand are sufficient to fund operations beyond the anticipated FDA decision of VenoValve and the initiation of the enVVe pivotal trial
FDA decision on PMA application for the VenoValve expected in the second half of 2025
On track for enVVe IDE...

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Wed, 23 Apr 2025 08:00:00 EST

IRVINE, CA / ACCESS Newswire / April 23, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that the VenoValve® will be featured during a presentation at the Annual Charing Cross Symposium being held...

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Wed, 16 Apr 2025 08:30:00 EST

Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22^nd at 4:00 PM ET

IRVINE, CA / ACCESS Newswire / April 16, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that

The Impact of the VenoValve® on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Mon, 31 Mar 2025 09:00:00 EST

IRVINE, CA / ACCESS Newswire / March 31, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced its abstract has been accepted for presentation at the Society for Clinical Vascular Surgery (SCVS) 52^nd Annual...

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Fri, 28 Feb 2025 08:00:00 EST

Cash Burn of $5.2 million in Q4 remains in line with projected $4-5 million quarterly range
Cash and investments on hand are sufficient to fund operations beyond the anticipated regulatory approval of VenoValve and the initiation of the enVVe pivotal trial
PMA application for the VenoValve submitted, with FDA decision expected in the second half of 2025
On...

enVVeno Medical Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Wed, 19 Feb 2025 09:00:00 EST

On-demand video webcast now available here

IRVINE, CA / ACCESS Newswire / February 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it...

One-Year Data from the VenoValve® U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Wed, 19 Feb 2025 08:45:00 EST

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators.
PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the second half of 2025.
IRVINE, CA / ACCESS Newswire / February 19, 2025 /...

Interim Two-Year Follow-Up Data from the VenoValve® U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Fri, 07 Feb 2025 09:00:00 EST

Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.
78% of subjects maintained a clinically meaningful benefit of more than 3 points in rVCSS at 24 months, with an average improvement of 8.2 points among the responder cohort.
Subjects continued to experience a median 75%...

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Mon, 16 Dec 2024 08:50:00 EST

Successful Completion of All Planned Implants in GLP Study
enVVe Delivery System Demonstrates Consistent Performance
Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results

IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company...

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Wed, 27 Nov 2024 08:30:00 EST

Interviews with participating patients from the VenoValve® U.S. Pivotal Trial
Webcast replay from with the presenting Primary Investigators
Presentation with data from the VenoValve U.S. Pivotal Trial
Access the Recap Website Here!
IRVINE, CA / ACCESSWIRE / November 27, 2024 /...

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Wed, 20 Nov 2024 08:30:00 EST

85% Clinical Meaningful Benefit Responder Rate
7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort
75% Median Reduction in Pain (VAS)
87% Median Ulcer Area Reduction
97% Target Vein Patency Rate
Improvement in All Patient Reported Quality-of-Life...

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Tue, 19 Nov 2024 08:15:00 EST

Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium
Company to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20^th at 2:00 PM Eastern Time -

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

Thu, 31 Oct 2024 08:35:00 EST

Continued progress toward submission of 5^th and final module of FDA premarket approval (PMA) application for VenoValve® in Q4
GLP study for enVVe® transcatheter-based replacement venous valve underway; On track to file IDE approval for pivotal trial mid-2025
Ended the quarter with $48.4 million cash and investments on hand sufficient to fund operations beyond expected...

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe®

Mon, 28 Oct 2024 08:30:00 EST

First wave of implants successfully completed with updated delivery system performing very well
Company on schedule to be in position to apply for approval for enVVe pivotal trial mid-2025

IRVINE, CA / ACCESSWIRE / October 28, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of...

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

Thu, 26 Sep 2024 22:20:00 EST

IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the pricing of an underwritten public offering led by existing institutional investors of 4,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at a public offering price of $3.50 per share. The...

enVVeno Medical Corporation Announces Proposed Public Offering

Thu, 26 Sep 2024 16:05:00 EST

IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or pre-funded warrants in lieu thereof) in an underwritten public offering. enVVeno expects to grant the underwriter a...

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

Tue, 03 Sep 2024 09:00:00 EST

MedTech Marketing Leader with Significant New Product Launch Experience for Cardiovascular Devices
Key Addition to Commercial Team as Company Begins Planning for the VenoValve Monetization
Several Upcoming Company Milestones Planned for Q4 of 2024 Including:
Completion of PMA Submission Seeking FDA Approval for the...

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve®

Wed, 14 Aug 2024 09:00:00 EST

VenoValve PMA Approval Application Process Consists of the Submission of 5 Modules to the FDA
4 Modules Have Now Been Submitted, Reviewed, and Approved by the FDA
Company on Track to File the 5^th and Final Module in Q4 2024

IRVINE, CA / ACCESSWIRE / August 14, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the...

enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Thu, 01 Aug 2024 08:05:00 EST

- Ended the quarter with $39.1 million cash and investments on hand sufficient to fund operations, through the end of 2025, including potential PMA approval of VenoValve®
- Positive interim venous ulcer healing data showing significant improvement from the VenoValve pivotal trial presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting
- Company on track to file...

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Tue, 25 Jun 2024 09:00:00 EST

Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, June 27^th at 4:00 PM ET

IRVINE, CA / ACCESSWIRE / June 25, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief...

New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024

Mon, 17 Jun 2024 12:00:00 EST

IRVINE, CA / ACCESSWIRE / June 17, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that new interim venous ulcer healing data from the VenoValve U.S. pivotal trial will be presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting (VAM2024) being held June...

enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update

Wed, 08 May 2024 16:15:00 EST

- Ended the quarter with $42.9 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025
- Positive 11-month topline efficacy data presented at the 46^th Annual Charing Cross Symposium
- Company on track to file PMA Application seeking VenoValve® FDA approval in Q4...

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve® Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium

Wed, 24 Apr 2024 06:15:00 EST

Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement 3 Points) including:
9.29 Points for Patients at the Two-Year Milestone
8.08 Points for Patients at the One-Year Milestone
8.71 Points for Patients at the Six-Month...

New Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

Tue, 16 Apr 2024 09:00:00 EST

IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that additional topline efficacy data from the VenoValve U.S. pivotal trial will be presented at the 2024 Charing Cross International Symposium being held April 23^rd - 25^th in...

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

Tue, 09 Apr 2024 08:45:00 EST

Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve®
PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024
IRVINE, CA / ACCESSWIRE / April 9, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of...

enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity

Fri, 15 Mar 2024 09:00:00 EST

Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, March 21^st at 12:00 PM ET
IRVINE, CA / ACCESSWIRE / March 15, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that it will present at the Virtual...

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve® Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting

Wed, 06 Mar 2024 08:40:00 EST

97% of VenoValve Study Patients Showing Clinical Improvement at Six Months (as Measured by the Revised Venous Clinical Severity Score (rVCSS))
74% of the Study Patients Showing Clinical Meaningful Benefit from the VenoValve at Six Months (Improvement in rVCSS of 3 or More Points)
Average rVCSS Improvement Per Patient is 8 Points, More Than Two and a Half Times the Amount Needed to Show the...

enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Thu, 29 Feb 2024 16:15:00 EST

$46.4 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025
Topline efficacy data for VenoValve® U.S. pivotal trial to be presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
Continued progress toward launch of GLP study for enVVe® transcatheter-based...

Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024

Tue, 20 Feb 2024 08:30:00 EST

IRVINE, CA / ACCESSWIRE / February 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that topline efficacy data from the VenoValve U.S. pivotal trial will be presented at the 2024 American Venous Forum (AVF) Annual Meeting being held March 3-6, 2024 in Tampa, Florida. The...

enVVeno News powered by B2i Technologies - SmartWire

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe® System

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

enVVeno Medical Announces Reverse Stock Split

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

enVVeno Medical Updates Regulatory Status of VenoValve®

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve®

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Health Economic Study Shows That enVVeno Medical's VenoValve® Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

Three-Year VenoValve® First-in-Human Trial Data Published in the Annals of Vascular Surgery

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H25

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

The Impact of the VenoValve® on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

enVVeno Medical Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

One-Year Data from the VenoValve® U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Interim Two-Year Follow-Up Data from the VenoValve® U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe®

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

enVVeno Medical Corporation Announces Proposed Public Offering

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve®

enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024

enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve® Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium

New Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve® Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting

enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024